BR112022013027A2 - Construtos aav-abcd1 melhorados e uso para tratamento ou prevenção de adrenoleucodistrofia (ald) e/ou adrenomieloeuropatia (amn) - Google Patents
Construtos aav-abcd1 melhorados e uso para tratamento ou prevenção de adrenoleucodistrofia (ald) e/ou adrenomieloeuropatia (amn)Info
- Publication number
- BR112022013027A2 BR112022013027A2 BR112022013027A BR112022013027A BR112022013027A2 BR 112022013027 A2 BR112022013027 A2 BR 112022013027A2 BR 112022013027 A BR112022013027 A BR 112022013027A BR 112022013027 A BR112022013027 A BR 112022013027A BR 112022013027 A2 BR112022013027 A2 BR 112022013027A2
- Authority
- BR
- Brazil
- Prior art keywords
- ald
- amn
- prevention
- treatment
- adrenomyeloeuropathy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962955667P | 2019-12-31 | 2019-12-31 | |
| PCT/US2020/067664 WO2021138559A1 (en) | 2019-12-31 | 2020-12-31 | Improved aav-abcd1 constructs and use for treatment or prevention of adrenoleukodystrophy (ald) and/or adrenomyeloneuropathy (amn) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022013027A2 true BR112022013027A2 (pt) | 2022-09-06 |
Family
ID=76686949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022013027A BR112022013027A2 (pt) | 2019-12-31 | 2020-12-31 | Construtos aav-abcd1 melhorados e uso para tratamento ou prevenção de adrenoleucodistrofia (ald) e/ou adrenomieloeuropatia (amn) |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11779655B2 (https=) |
| EP (1) | EP4085143B1 (https=) |
| JP (1) | JP2023509443A (https=) |
| KR (1) | KR20220128632A (https=) |
| CN (1) | CN116096904A (https=) |
| AU (1) | AU2020416291A1 (https=) |
| BR (1) | BR112022013027A2 (https=) |
| CA (1) | CA3166374A1 (https=) |
| IL (1) | IL294278A (https=) |
| MX (1) | MX2022008201A (https=) |
| WO (1) | WO2021138559A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3228344A1 (en) * | 2021-08-06 | 2023-02-09 | Wuhan Neurophth Biotechnology Limited Company | Composition and method for treating leber's hereditary optic neuropathy caused by nd4 mutation |
| KR20250009975A (ko) * | 2022-05-12 | 2025-01-20 | 아브너진 인코포레이티드 | 재조합 파르보바이러스 생산을 위한 조성물 및 방법 |
| EP4536862A1 (en) * | 2022-06-09 | 2025-04-16 | Wisconsin Alumni Research Foundation | Generation of next generation recombinant aav gene therapy vectors that adopt 3d conformation |
| AU2024315073A1 (en) * | 2023-07-28 | 2026-01-22 | Regeneron Pharmaceuticals, Inc. | Use of bgh-sv40l tandem polya to enhance transgene expression during unidirectional gene insertion |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ532635A (en) | 2001-11-13 | 2007-05-31 | Univ Pennsylvania | A method of identifying unknown adeno-associated virus (AAV) sequences and a kit for the method |
| DK2359869T3 (en) | 2001-12-17 | 2019-04-15 | Univ Pennsylvania | Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof |
| CN1856576B (zh) | 2003-09-30 | 2011-05-04 | 宾夕法尼亚州立大学托管会 | 腺伴随病毒(aav)进化支、序列、含有这些序列的载体及它们的应用 |
| WO2006110689A2 (en) | 2005-04-07 | 2006-10-19 | The Trustees Of The University Of Pennsylvania | Method of increasing the function of an aav vector |
| US7588772B2 (en) | 2006-03-30 | 2009-09-15 | Board Of Trustees Of The Leland Stamford Junior University | AAV capsid library and AAV capsid proteins |
| US8466271B2 (en) * | 2008-07-23 | 2013-06-18 | Boehringer Ingelheim Pharma Gmbh & Co, Kg | Regulatory elements |
| US8865881B2 (en) * | 2011-02-22 | 2014-10-21 | California Institute Of Technology | Delivery of proteins using adeno-associated virus (AAV) vectors |
| RU2014100160A (ru) * | 2011-06-10 | 2015-07-20 | Блуберд Байо, Инк. | Векторы генной терапии адренолейкодистрофии и адреномиелонейропатии |
| US9163259B2 (en) * | 2012-05-04 | 2015-10-20 | Novartis Ag | Viral vectors for the treatment of retinal dystrophy |
| EP2940131B1 (en) * | 2012-12-25 | 2019-02-20 | Takara Bio Inc. | Aav variant |
| WO2015153889A2 (en) * | 2014-04-02 | 2015-10-08 | University Of Florida Research Foundation, Incorporated | Materials and methods for the treatment of latent viral infection |
| JP2018510160A (ja) * | 2015-03-20 | 2018-04-12 | ブルーバード バイオ， インコーポレイテッド | ベクター製剤 |
| CA3019315A1 (en) * | 2015-04-23 | 2016-10-27 | University Of Massachusetts | Modulation of aav vector transgene expression |
| MX2018005689A (es) | 2015-11-05 | 2018-08-01 | Massachusetts Gen Hospital | Administracion intratecal de secuencias de acido nucleico que codifican abcd1 para el tratamiento de la adrenomieloneuropatia. |
| PL3411484T3 (pl) * | 2016-02-05 | 2024-02-19 | Emory University | Wstrzykiwanie jednoniciowego lub samokomplementarnego wirusa adenosatelitarnego 9 do płynu mózgowego |
| EP3413925A1 (en) * | 2016-02-12 | 2018-12-19 | Combigene AB | Vector |
| CN107287239B (zh) * | 2016-04-11 | 2020-09-22 | 厦门继景生物技术有限责任公司 | 一种用于视网膜色素变性的基因治疗载体及药物 |
| CN109843306A (zh) * | 2016-08-19 | 2019-06-04 | 卡琳缪恩股份有限公司 | 使用自身互补型重组腺相关病毒治疗病症的方法和组合物 |
| WO2018136434A1 (en) * | 2017-01-17 | 2018-07-26 | Children's Medical Center Corporation | Compositions and methods for diagnosing and treating peroxisomal diseases |
| EP3592137B1 (en) * | 2017-03-10 | 2024-08-07 | The Medical College of Wisconsin, Inc. | Riboswitch modulated gene therapy for retinal diseases |
| WO2019060649A1 (en) * | 2017-09-22 | 2019-03-28 | Voyager Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR TREATING HUNTINGTON'S DISEASE |
| MX2020004092A (es) * | 2017-10-18 | 2021-01-08 | Composiciones de virus adenoasociados para restaurar la funcion del gen hbb y metodos de uso de estas. | |
| GB201817470D0 (en) * | 2018-10-26 | 2018-12-12 | Univ Oxford Innovation Ltd | Gene therapy |
-
2020
- 2020-12-31 EP EP20909162.8A patent/EP4085143B1/en active Active
- 2020-12-31 BR BR112022013027A patent/BR112022013027A2/pt unknown
- 2020-12-31 AU AU2020416291A patent/AU2020416291A1/en active Pending
- 2020-12-31 WO PCT/US2020/067664 patent/WO2021138559A1/en not_active Ceased
- 2020-12-31 CA CA3166374A patent/CA3166374A1/en active Pending
- 2020-12-31 MX MX2022008201A patent/MX2022008201A/es unknown
- 2020-12-31 IL IL294278A patent/IL294278A/en unknown
- 2020-12-31 JP JP2022540917A patent/JP2023509443A/ja active Pending
- 2020-12-31 CN CN202080097613.5A patent/CN116096904A/zh active Pending
- 2020-12-31 KR KR1020227026264A patent/KR20220128632A/ko not_active Ceased
-
2021
- 2021-12-21 US US17/557,409 patent/US11779655B2/en active Active
-
2023
- 2023-08-30 US US18/458,665 patent/US20240009326A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11779655B2 (en) | 2023-10-10 |
| IL294278A (en) | 2022-08-01 |
| MX2022008201A (es) | 2022-10-18 |
| US20220175965A1 (en) | 2022-06-09 |
| CA3166374A1 (en) | 2021-07-08 |
| EP4085143A1 (en) | 2022-11-09 |
| EP4085143B1 (en) | 2025-08-13 |
| CN116096904A (zh) | 2023-05-09 |
| US20240009326A1 (en) | 2024-01-11 |
| JP2023509443A (ja) | 2023-03-08 |
| WO2021138559A1 (en) | 2021-07-08 |
| EP4085143A4 (en) | 2024-02-28 |
| US20220362403A2 (en) | 2022-11-17 |
| AU2020416291A1 (en) | 2022-07-21 |
| KR20220128632A (ko) | 2022-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022013027A2 (pt) | Construtos aav-abcd1 melhorados e uso para tratamento ou prevenção de adrenoleucodistrofia (ald) e/ou adrenomieloeuropatia (amn) | |
| PH12020500663A1 (en) | Brm targeting compounds and associated methods of use | |
| MX2022001328A (es) | Inhibidor de proteina quinasa quinasa activada por mitogeno (mek) para el tratamiento de apoplejia. | |
| MY206825A (en) | Pyridazinyl thiazolecarboxamide compound | |
| BR112018009645A2 (pt) | composições e métodos para a expressão de vários polipeptídeos biologicamente ativos a partir de um único vetor para tratamento de condições cardíacas e outras patologias | |
| BR112021015751A2 (pt) | Vetores de terapia genética para tratamento da doença de danon | |
| BR112022008214A2 (pt) | Composições e métodos para tratar perda auditiva neurossensorial usando sistemas de vetor duplo de otoferlina | |
| BR112017023380A2 (pt) | sistema, composição cosmética, métodos para tratamento de substratos queratinosos e para proteção e/ou alisamento da fibra do cabelo, kit multicompartimento, e, processo para alisamento do cabelo. | |
| MX2022005132A (es) | Terapia combinada con formulaciones de anticuerpos anti-pvrig y anticuerpos anti-pd-1. | |
| BR112017025813A2 (pt) | método, kit ou composição, micróbio comensal benéfico, método para tratar ou prevenir o câncer e formulação bacteriana | |
| BR112019022280A2 (pt) | tratamento de cânceres de her2 positivo | |
| BR112021022951A2 (pt) | Composições e métodos para o tratamento de doenças mediadas por atpase | |
| BR112019017393A2 (pt) | formulações de evolocumab de baixa viscosidade, alta concentração e métodos para produzir as mesmas | |
| BR112021016783A2 (pt) | Composições e métodos para tratar laminopatias | |
| JOP20230250A1 (ar) | تركيبات وطرق لتثبيط إنزيم كيتوهيكسوكيناز (khk) | |
| CO2022000270A2 (es) | Inhibidores de enzimas | |
| MX2022010186A (es) | Neurotoxinas botulinas para uso en terapia. | |
| PH12021550122A1 (en) | Solubilized apyrases, methods and use | |
| EA201890119A1 (ru) | Смешанные составы | |
| WO2018140853A8 (en) | Transglutaminase treated products | |
| BR112019004791A2 (pt) | tratamento de esclerose múltipla com chs-131 | |
| GB2564990A8 (en) | Topical compositions for neuropathic pain | |
| AR117094A1 (es) | Moduladores de expresión irf5 | |
| BR112020004935A2 (pt) | Composição farmacêutica compreendendo um anticorpo que se liga especificamente a n-terminal de lisil-trna sintetase como princípio ativo para prevenção ou tratamento de doença relacionada com migração celular | |
| PH12018501508A1 (en) | Depilatory compositions |